145 related articles for article (PubMed ID: 16137214)
1. Economic burden of anemia in an insured population.
Nissenson AR; Wade S; Goodnough T; Knight K; Dubois RW
J Manag Care Pharm; 2005 Sep; 11(7):565-74. PubMed ID: 16137214
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of patients with anemia in selected diseases.
Ershler WB; Chen K; Reyes EB; Dubois R
Value Health; 2005; 8(6):629-38. PubMed ID: 16283863
[TBL] [Abstract][Full Text] [Related]
3. The economic burden of anemia in cancer patients receiving chemotherapy.
Lyman GH; Berndt ER; Kallich JD; Erder MH; Crown WH; Long SR; Lee H; Song X; Finkelstein SN
Value Health; 2005; 8(2):149-56. PubMed ID: 15804323
[TBL] [Abstract][Full Text] [Related]
4. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
Margolis J; Barron JJ; Grochulski WD
J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
[TBL] [Abstract][Full Text] [Related]
5. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
6. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States.
St Peter WL; Guo H; Kabadi S; Gilbertson DT; Peng Y; Pendergraft T; Li S
BMC Nephrol; 2018 Mar; 19(1):67. PubMed ID: 29544446
[TBL] [Abstract][Full Text] [Related]
8. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
Prescott JD; Factor S; Pill M; Levi GW
J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
10. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
11. Actuarial analysis of private payer administrative claims data for women with endometriosis.
Mirkin D; Murphy-Barron C; Iwasaki K
J Manag Care Pharm; 2007 Apr; 13(3):262-72. PubMed ID: 17407392
[TBL] [Abstract][Full Text] [Related]
12. Direct costs of opioid abuse in an insured population in the United States.
White AG; Birnbaum HG; Mareva MN; Daher M; Vallow S; Schein J; Katz N
J Manag Care Pharm; 2005; 11(6):469-79. PubMed ID: 15998164
[TBL] [Abstract][Full Text] [Related]
13. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
14. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus.
Delea TE; Gokhale M; Makin C; Hussein MA; Vanderpoel J; Sandman T; Chang J; Sung J; Pinkston P; Gause D; Jackson M
J Manag Care Pharm; 2007 May; 13(4):349-59. PubMed ID: 17506601
[TBL] [Abstract][Full Text] [Related]
15. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
16. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
[TBL] [Abstract][Full Text] [Related]
17. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.
Bickston SJ; Waters HC; Dabbous O; Tang BI; Rahman M
J Manag Care Pharm; 2008 May; 14(4):352-62. PubMed ID: 18500913
[TBL] [Abstract][Full Text] [Related]
18. Anemia in chronic obstructive pulmonary disease: epidemiology and economic implications.
Shorr AF; Doyle J; Stern L; Dolgitser M; Zilberberg MD
Curr Med Res Opin; 2008 Apr; 24(4):1123-30. PubMed ID: 18331668
[TBL] [Abstract][Full Text] [Related]
19. What Contributes Most to High Health Care Costs? Health Care Spending in High Resource Patients.
Pritchard D; Petrilla A; Hallinan S; Taylor DH; Schabert VF; Dubois RW
J Manag Care Spec Pharm; 2016 Feb; 22(2):102-9. PubMed ID: 27015249
[TBL] [Abstract][Full Text] [Related]
20. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
